

WAIVING CERTAIN ENROLLMENT REQUIREMENTS

Mr. LOTT. Mr. President, I ask unanimous consent that the Senate now turn to House Joint Resolution 90, regarding hand enrollment, that the joint resolution be passed, and the motion to reconsider be laid upon the table.

The PRESIDING OFFICER. Without objection, it is so ordered.

The joint resolution (H.J. Res. 90) was passed.

CORRECTING TECHNICAL ERRORS IN THE ENROLLMENT OF H.R. 2014

Mr. LOTT. Mr. President, I ask unanimous consent that the Senate now turn to the consideration of a House concurrent resolution that corrects the enrollment of the tax fairness conference report, that there be no amendments in order, that the concurrent resolution be agreed to, and the motion to reconsider be laid upon the table, all without intervening action or debate.

The PRESIDING OFFICER. Without objection, it is so ordered.

The Concurrent Resolution (H. Con. Res. 138) was agreed to.

UNANIMOUS-CONSENT AGREEMENT—H.R. 2160

Mr. LOTT. Mr. President, I ask unanimous consent that at 2:15 p.m. on Tuesday, September 2, the Senate turn to the consideration of H.R. 2160, the House Agriculture Appropriations bill, and one amendment be in order to be offered by Senator HARKIN regarding FDA and there be 20 minutes for debate to be equally divided in the usual form.

I further ask that following the conclusion or yielding back of time, the amendment be laid aside until 9:30 a.m. on Wednesday, September 3, and there be 30 minutes for closing debate to be equally divided, and following that debate, the Senate proceed to a vote on or in relation to the Harkin amendment.

I further ask that immediately following the vote in relation to the Harkin amendment, all after the enacting clause be stricken, the text of the Senate bill be inserted, including the Harkin amendment, if agreed to, and H.R. 2160 be advanced to third reading and agreed to, and the Senate insist on its amendment, request a conference with the House and the Chair be authorized to appoint conferees on the part of the Senate.

The PRESIDING OFFICER. Without objection, it is so ordered.

FOOD AND DRUG ADMINISTRATION MODERNIZATION AND ACCOUNTABILITY ACT OF 1997

Mr. LOTT. Mr. President, a lot of effort has been put into the Food and Drug Administration reform legislation. The committee reported it out by a, I believe, 14 to 4 vote. It was an over-

whelming bipartisan vote. A tremendous effort has been underway to get an agreement on that legislation and to bring it to the floor. I think we should do that and, if I have to, I will begin a cloture proceeding the week we come back because I think this reform is very important. Some parts of it in the law will expire, I believe, at the end of August and will begin to have an impact in September and October.

I ask unanimous consent that the Senate now turn to the consideration of S. 830 regarding FDA reform.

Mr. KERRY. Mr. President, on behalf of the leadership, I do object.

The PRESIDING OFFICER. Objection is heard.

FDA REFORM

Mr. LOTT. Mr. President, this is the second time this week I have been blocked from trying to move to consideration of critical FDA reform legislation.

This bill, the FDA Modernization and Accountability Act, would ensure that patients and consumers have prompt access to safe and effective products, including prescription drugs, medical devices, and foods.

It would streamline the FDA bureaucracy, which has spun dangerously out of control in recent years. And, it would reauthorize the Prescription Drug User Fee Act.

I am greatly disappointed that this bill is being held hostage by a small number of Senators. This legislation enjoys strong bipartisan support. It passed the Labor Committee by a bipartisan vote of 14 to 4.

Since the bill passed committee on June 18, supporters of FDA reform have tried repeatedly to address the concerns of these four opponents. In fact, supporters of reform have made an additional 30 concessions in the bill since it was reported from committee.

Cosponsors of the bill, Democrat and Republican alike, met with Senator KENNEDY this morning in a last ditch effort to convince him to let the bill go forward. Despite the bill's strong bipartisan support and despite these additional compromises, he refused.

This legislation is too important to be held hostage. As such, I intend to bring the committee-passed FDA reform bill to the floor in September. If necessary, I will file cloture to ensure that this important piece of business for the health of the American people is completed in a timely manner.

FDA REFORM

Mr. KENNEDY. Mr. President, I regret that we have been unable to reach final agreement so far on FDA reform. In fact, the negotiations this month have made significant progress on almost all of the issues surrounding the bill. Reasonable compromises were reached on 26 separate proposals that had raised serious health and safety concerns and were opposed by the FDA and the administration.

Two issues remained today. It is critical that FDA be able to get all the data they need to ensure that devices that have different technological characteristics from a predecessor device are safe and effective. Provisions of the committee-reported bill might unduly tie the FDA's hands in this important area.

The second issue involves the proposal for sweeping Federal pre-emption of the current authority of States to regulate over-the-counter drugs and cosmetics. In cosmetics, for example, there is virtually no significant Federal regulation at the present time, and States should have the right to act to protect their citizens against dangerous products. Too often, there have been abuses such as lipsticks containing substances that could cause birth defects, skin creams made with known carcinogens, excessive lead in hair dye, and suntan products that produce severe chemical burns.

In my view, acceptable compromises can be reached on both of these issues, and I hope that good faith negotiations will continue.

Unfortunately, in the wake of the current impasses on these two issues, several additional matters that had previously been settled have now been reopened. A fair overall compromise is still possible that adequately protects the public, and I am optimistic that we can achieve it by September.

GLOBAL CLIMATE CHANGE OBSERVER GROUP

Mr. LOTT. Mr. President, under the provisions of Senate Resolution 98 regarding global climate change, the two leaders have the authority to appoint 12 Senators to serve on the Global Climate Change Observer Group.

Last week, the Senate adopted the Hagel-Byrd resolution regarding global climate change. This resolution encouraged the creation of a bipartisan group of Senators to monitor the status of negotiations on global climate change and to report periodically to the Senate on those negotiations.

As such, the minority leader and I have appointed 12 Senators to serve on this Global Climate Change Observer Group.

Due to their diligent efforts on the global climate issue, I have asked our colleague from Nebraska, CHUCK HAGEL, to serve as chairman, and the distinguished gentleman from West Virginia, ROBERT BYRD, to serve as co-chairman of the group.

The other Members of the observer group will include Senators ABRAHAM, CHAFEE, CRAIG, MURKOWSKI, ROBERTS, BAUCUS, BINGAMAN, KERRY, LEVIN, and LIEBERMAN.

I greatly appreciate our colleagues' willingness to take on this important task and look forward to hearing their reports.